Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  UnitedHealth Group    UNH

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Jordan Dufee

share with twitter share with LinkedIn share with facebook
share via e-mail

Technically solid

Strategy published on 08/02/2017 | 17:06
long trade
Target price hit
Entry price : 192.95$ | Target : 220$ | Stop-loss : 183$ | Potential : 14.02%
Shares in UnitedHealth Group do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the $ 220.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

  • Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
  • As regards fundamentals, the enterprise value to sales ratio is at 1 for the current period. Therefore, the company is undervalued.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 158.66 USD
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 225 B
EBIT 2018 17 433 M
Net income 2018 11 440 M
Debt 2018 14 676 M
Yield 2018 1,28%
P/E ratio 2018 19,41
P/E ratio 2019 17,07
EV / Sales 2018 1,05x
EV / Sales 2019 0,95x
Capitalization 220 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
UnitedHealth Group Technical Analysis Chart | UNH | US91324P1021 | 4-Traders
Duration : Period : Week
UnitedHealth Group Technical Analysis Chart | UNH | US91324P1021 | 4-Traders